Swedish Orphan Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for SWEDISH ORPHAN, and when can generic versions of SWEDISH ORPHAN drugs launch?
SWEDISH ORPHAN has two approved drugs.
There is one US patent protecting SWEDISH ORPHAN drugs.
There are twenty-one patent family members on SWEDISH ORPHAN drugs in twenty-two countries and three supplementary protection certificates in three countries.
Summary for Swedish Orphan
| International Patents: | 21 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Swedish Orphan
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-001 | Jan 18, 2002 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
| Swedish Orphan | ORFADIN | nitisinone | SUSPENSION;ORAL | 206356-001 | Apr 22, 2016 | RX | Yes | Yes | 9,301,932 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-004 | Jun 13, 2016 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-002 | Jan 18, 2002 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Swedish Orphan
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-001 | Jan 18, 2002 | 5,006,158 | See Plans and Pricing |
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-003 | Jan 18, 2002 | 5,006,158 | See Plans and Pricing |
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-003 | Jan 18, 2002 | 5,550,165 | See Plans and Pricing |
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-002 | Jan 18, 2002 | 5,550,165 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Swedish Orphan Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 110979 | See Plans and Pricing |
| Japan | 2014517067 | See Plans and Pricing |
| Japan | 6038132 | See Plans and Pricing |
| Denmark | 2723320 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Swedish Orphan Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0591275 | SPC/GB05/030 | United Kingdom | See Plans and Pricing | PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221 |
| 0591275 | 05C0024 | France | See Plans and Pricing | PRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221 |
| 0591275 | C300198 | Netherlands | See Plans and Pricing | PRODUCT NAME: NITISINONE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/303/001-003 20050201 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
